SUPN
Supernus Pharmaceuticals Inc
42.40$
+0.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +25.3% | -14.6% | -7.2% | +50.2% | -17.0% | -31.1% | +91.3% | -205.3% | – | +234.9% | -107.2% | – | |
| – | -0.8% | -4.3% | -0.1% | -3.0% | -6.2% | +8.2% | +4.8% | +16.1% | +271.6% | -71.6% | -1.6% | – | |
| – | -18.6% | -8.5% | +11.1% | +17.1% | -0.5% | +5.7% | -7.0% | +4.2% | +322.4% | -74.3% | +1.9% | – | |
| – | -93.3% | +602.4% | -120.9% | – | – | – | -17.4% | -528.1% | – | – | -112.8% | – | |
| – | -76.0% | +588.9% | -74.2% | +212.5% | +6.5% | +53.5% | +39.1% | -71.6% | +231.0% | -100.0% | – | – | |
| – | -290.5% | -21.8% | -5.9% | +58.5% | -83.6% | – | -182.0% | – | -205.3% | -62.5% | – | – | |
| – | +765.2% | -32.7% | -99.9% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +43.8% | +5.6% | +85.5% | +91.5% | -463.3% | – | +2,153.3% | -59.5% | +6.9% | -179.0% | – | |
| – | -128.4% | – | – | – | – | +23.5% | -38.0% | -71.9% | -382.7% | – | -108.7% | – | |
| – | +25.9% | -15.2% | -6.8% | +49.9% | -17.1% | -31.5% | +91.9% | -206.4% | – | +242.3% | -108.1% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.